The facility will house a fermentation reactor sized at 30,000 L, which is the largest of its kind. This will allow the total manufacturing volume reach up to 900,000 L.
Israel-based Kibbutz Yotvata and Brevel signed an agreement to build a commercial-scale manufacturing facilityfor cultivating and producingmicroalgae-based protein and other products for the food and beverage industry. The facility will house a fermentation reactor sized at 30,000 L, which is the largest of its kind. This will allow the total manufacturing volume reach up to 900,000 L and 3,000 tons of dry product per year; an upgrade from Brevel’s current fermenters that have a capacity of 5,000 L. Once the facility is completed, the parties expect to export to customers abroad at least 25% of its production to various markets.
“We are proud to build the largest facility of its kind in the world, which will be producing microalgae on a commercial scale to support rising demand in various markets,” said Hannan Shushan, Yotvata's CEO, in a press release. “Yotvata is dedicated towards finding sustainable solutions to feed the ever-growing world population and believes that the alternative-protein market will play a big part in that mission. The agreement with Brevel is a significant step in that direction.”
Yonatan Golan, CEO and co-founder of Brevel, said the agreement is a milestone for microalgae-based alternative protein. “This first commercial scale manufacturing facility will enable us to move our vision forward: to become the number one choice for plant-based protein worldwide,” Golan said. “We are actively working to solve the biggest nutrition challenges that exist today. The company is achieving this by providing truly sustainable plant-based protein, which is both color and flavor neutral, and available for the first time at an affordable cost for the food industry.”
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.